And now I will hand the floor to the president, Mr. Antonio Llarden. 
Mr. Javier Suarez from Mediobanca. First question. 
We have recently filed for orphan drug designation for ADX- 2191 in PVRL. 
Your next question comes from the line of Camilo Lyon with BTIG. Please proceed with your question. 
And how should we think about the, uh CAFEX traj- trajectory from 21, and beyond? Is that more in line with what you disclosed at your analyst day, 
I think in terms of Sandy Cooper, uh, you know, that process has been pushed to next year, and we remain, 
Joc, another question comes to you from Jonas Oscar of Bernstein. 
Okay. Thank you very much. And Jasonâ€¦ It's Melissa, one other thing- Sure. to just keep in mind, there is a little bit of a timing impact from the Nielsen and IRI data, given that the season was on a Saturday versus a Thursday, and based on retail recording days. 
I'm joined by our CFO, Markus Krebber, who will run through the presentation before we move on to Q&As later in the call. 
Despite the small to medium double digit million euro negative impact from tighter commissioning phases, and the delay at Big Raymond and <unk> 
Good afternoon. I'm Avanda Savinasca, Credit Suisse, two questions from me. 
Our first question comes from the line of Brad Heffern with RBC Capital Markets. Please proceed with your question. 
Um, but let's see how the draft will go through parliament, but the draft version at least looks very favorable for the industry. Perfect. Thank you. Thank you, Deepa. Next question please. 
We obviously are continuing to work with, uh, Missouri Public Service Commission, the staff, the OPC, and the other interveners to, um, not only Crispin <inaudible> up the, um, the support for our filings, 
percent. So, the Aspen, 10 West and Clover House has properties currently are least ranging from 92 to 95%. 
Thank you, Mr. Gandolfi. 
Thanks Christelle. Good morning everyone and thanks for joining us on the call. 
We expect this market to grow with a CAGR of about 27% to 15 billion in 203. 
Good morning, welcome to the New Home Company earning conference call. Earlier today the company released its financial results for the third quarter of 2020. 
Last quarter, we talked about our expanded multi-year partnership with Google and Deloitte to enhance our Omni-channel shopping experience. 
Since announcing a restructuring in late 2018, Dentsply Sirona has made significant progress against the goals we had laid out. 
that's really a product mix, uh, dynamic. In the select business we have the thrust of the premium is two products, CMT and workers comp. 
as well as our recent distribution and promotion agreement with Zimmer Biomet, for DSUVIA for the management of acute pain in adults during dental and oral surgeries. 
and representing a decrease of 10.9% from RMB 339.9 million the same period of last year. 
